Datavault AI Inc. (NASDAQ: DVLT) has expanded its definitive licensing agreement with DataMeds AI Inc. (NASDAQ: MEDS), extending its PharmacyChain blockchain technology beyond pharmaceutical distribution into commercial healthcare, healthspan, and wellness applications. The amended agreement, announced in a press release, is designed to support patient-controlled health data access, monetization, and real-world asset tokenization across pharmacy, medical, laboratory, and wearable device environments.
The expanded relationship leverages a behavioral healthcare patent portfolio focused on medical logistics, IoT population health, and AI-driven remote patient monitoring. Under the terms of the amended agreement, Datavault AI will receive common shares representing approximately 19.9% of DataMEDS’ outstanding common stock upon closing of previously announced related transactions, replacing the preferred shares originally contemplated for tax optimization purposes. The companies said the agreement accelerates deployment of Datavault AI’s technology into the healthcare sector, targeting opportunities within the rapidly expanding global health and wellness market while enabling new patient-controlled data transaction models.
This development is significant because it moves Datavault AI’s blockchain and data monetization technologies into a high-growth sector where patient-controlled data is increasingly valued. The global health and wellness market, which includes digital health, wearable devices, and personalized medicine, is projected to grow substantially, and Datavault AI’s platform could enable new revenue streams for patients and healthcare providers alike. By allowing patients to control and monetize their own health data, the company is addressing a key trend in healthcare: the shift toward patient empowerment and data privacy, which aligns with regulations like HIPAA and GDPR.
Datavault AI’s technology suite includes its cloud-based platform for AI-driven data experiences, valuation, and monetization in the Web 3.0 environment. The company’s Data Science division leverages high-performance computing for experiential data perception and secure monetization, while its Acoustic Sciences division features WiSA, ADIO, and Sumerian patented technologies for spatial audio. The platform serves multiple industries, including healthcare, biotech, fintech, and real estate, through its Information Data Exchange, which enables Digital Twins and secure licensing of name, image, and likeness.
The expansion into commercial healthcare represents a strategic move for Datavault AI, as it diversifies beyond its core markets. The partnership with DataMEDS, which focuses on AI-driven healthcare solutions, provides a direct channel into the healthcare industry. According to the press release, the companies aim to deploy Datavault AI’s technology in pharmacy, medical, laboratory, and wearable device settings, targeting the growing demand for patient-controlled health data models.
For more information on Datavault AI, visit https://dvlt.ai. The full press release is available at https://ibn.fm/vBAxH.
